atr-258
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 11, 2022 (NCT05409924)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Beta-2 adrenergic receptorAGONIST
ADRB2 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06432673 | Phase 1 | Apr 24, 2024 | Atrogi AB |
| NCT05409924 | Phase 1 | Apr 11, 2022 | Atrogi AB, CRS Clinical Research Services Kiel GmbH, Key2Compliance |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Atrogi AB | For profit | 2 | 2 | 1 | 2022 |
| CRS Clinical Research Services Kiel GmbH | For profit | 1 | 0 | 1 | 2022 |
| Key2Compliance | For profit | 1 | 0 | 1 | 2022 |
3 organizations
Page 1 / 1